Related Experiment Video
Updated: Feb 1, 2026
The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
Published on: June 30, 2014
Siponimod for the treatment of secondary progressive multiple sclerosis
Laura Dumitrescu1, Cris S Constantinescu2, Radu Tanasescu1,2
1a Department of Neurosciences, University of Medicine and Pharmacy Carol Davila, Department of Neurology , Colentina Hospital , Bucharest , Romania.
Introduction:
Multiple sclerosis (MS) is a chronic central nervous system immune-mediated disease with an important inflammatory component associated with focal demyelination and widespread neurodegeneration. In most cases, the clinical presentation is relapsing-remitting, followed by a secondary progressive phase, characterized by disability accrual unrelated to relapses. In a minority, the phenotype is progressive from the beginning. Major therapeutic achievements have been made concerning the relapsing phase but modifying the evolution of progressive MS remains an unmet need. Areas covered: This review covers siponimod (BAF312), a new sphingosine 1-phosphate receptor modulator, and its role in the treatment of secondary progressive MS. The authors reviewed PubMed English literature using the keywords 'siponimod' or 'BAF312' and 'multiple sclerosis.' They also present the pharmacological profile of siponimod, as well as clinical efficacy and safety, with emphasis on the recently published results of a Phase III trial. Phase II data in relapsing MS are also summarized. Expert opinion: Siponimod may reduce the activity of the disease and has a modest effect on the gradual disability accrual. If approved, it may become one of the few available therapy options for secondary progressive MS.
Insights
Siponimod offers a potential new treatment for secondary progressive multiple sclerosis (MS) by targeting sphingosine 1-phosphate receptors. It may help reduce disease activity and slow disability progression in MS patients.
Area of Science:
- Neuroimmunology
- Pharmacology
Background:
- Multiple sclerosis (MS) is a chronic, immune-mediated central nervous system disease with inflammatory and neurodegenerative components.
- While treatments exist for relapsing MS, modifying progressive MS remains a significant unmet medical need.
- Secondary progressive MS is characterized by gradual disability accrual independent of relapses.
Purpose of the Study:
- To review the role of siponimod (BAF312) in treating secondary progressive multiple sclerosis (SPMS).
- To present the pharmacological profile, clinical efficacy, and safety of siponimod.
- To summarize findings from Phase II and Phase III trials of siponimod in MS.
Main Methods:
- Literature review of PubMed using keywords 'siponimod' or 'BAF312' and 'multiple sclerosis'.
- Analysis of pharmacological data, clinical trial results (Phase II and III), and safety profiles.
- Focus on recently published Phase III trial data for siponimod in SPMS.
Main Results:
- Siponimod is a sphingosine 1-phosphate (S1P) receptor modulator.
- Phase III trial data suggests siponimod may reduce disease activity.
- The drug demonstrated a modest effect on slowing gradual disability accrual in SPMS patients.
Conclusions:
- Siponimod shows potential as a therapeutic option for secondary progressive multiple sclerosis.
- It may offer a new way to manage disease activity and disability progression in SPMS.
- If approved, siponimod could be one of the limited therapies available for progressive MS.
Related Concept Videos
01:55Secondary Active Transport
01:32Secondary Active Transport
01:11Secondary Healthcare System
03:02Primary and Secondary Growth in Roots and Shoots
01:25Secondary Distribution
In residential areas, 120/240 V single-phase, three-wire service is commonly used for lighting, outlets, and large appliances. Urban areas with high-density loads...
01:49Multiple Allele Traits